Coronavirus (COVID-19) Update
AmerisourceBergen and our global businesses are highly engaged during the ongoing spread of the novel COVID-19 “Coronavirus."
Read our latest update

US Bioservices is now dispensing DUPIXENT

March 30, 2017

The U.S. Food and Drug Administration recently approved Sanofi and Regeneron’s DUPIXENT (dupilumab) for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.